Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY)
Abstract
Introduction Maturity-onset diabetes of the young (MODY), particularly due to HNF1A variants, is usually treated with sulfonylureas or insulin. In patients with excess weight or poor glycaemic control, these approaches can be challenging. Incretin-based therapies may provide a safer and more effective alternative. Methods We conducted a retrospective case series at Tawam Hospital (2019-2024), including patients with genetically confirmed MODY who received a Glucagon-like peptide-1 (GLP-1) receptor agonist or dual GLP-1/Glucose-dependent insulinotropic polypeptide (GIP) receptor agonist for at least three months. Clinical data, including HbA1c, body mass index (BMI), and insulin use, were extracted from medical records. The primary outcome was change in HbA1c; secondary outcomes included changes in BMI and insulin requirements. Results Six patients were included (five with HNF1A variants, one with combined PAX4/PDX1 variants). At baseline, HbA1c ranged from 7.3% to 10.6% and BMI from 25.1 to 36.7 kg/m². Following treatment, HbA1c improved in all cases (reductions of 1.0-4.1 percentage points) and weight decreased by 2.6-29 kg. Three of four insulin-treated patients discontinued insulin, while insulin-naïve patients maintained good glycaemic control without insulin initiation. Conclusion GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists improved glycaemic control, reduced body weight, and decreased insulin dependency in MODY patients. These findings suggest…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.